Jasmine Sukumar MD
@jasminesukumar.bsky.social
Breast Medical Oncologist @mdanderson.bsky.social #bcsm #oncsky
Reposted by Jasmine Sukumar MD
🎉Reunion w/ my co-fellow @jasminesukumar.bsky.social @mdanderson.bsky.social to discuss early #breastcancer adj tx w/ path germline muts on the @ascocancer.bsky.social Daily News podcast
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
ASCO Daily News: Advances in Adjuvant Therapy for High-Risk Early Breast Cancer With Germline Mutations
Dr. Jessica Sukumar and Dr. Dionisia Quiroga discuss advances in adjuvant therapy for patients with early breast cancer and BRCA1/2 mutations, including how to identify patients who should receive gen...
ascodaily.libsyn.com
February 2, 2025 at 7:44 PM
🎉Reunion w/ my co-fellow @jasminesukumar.bsky.social @mdanderson.bsky.social to discuss early #breastcancer adj tx w/ path germline muts on the @ascocancer.bsky.social Daily News podcast
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
Reposted by Jasmine Sukumar MD
🔻 Cancer mortality declined, averting 4.5M deaths since 1991, thanks to smoking reduction, earlier detection, & better treatments.
🔺 However, alarming disparities persist
🚺 Cancer incidence is rising in women
@oncoalert.bsky.social
acsjournals.onlinelibrary.wiley.com/doi/full/10....
🔺 However, alarming disparities persist
🚺 Cancer incidence is rising in women
@oncoalert.bsky.social
acsjournals.onlinelibrary.wiley.com/doi/full/10....
January 17, 2025 at 1:59 PM
🔻 Cancer mortality declined, averting 4.5M deaths since 1991, thanks to smoking reduction, earlier detection, & better treatments.
🔺 However, alarming disparities persist
🚺 Cancer incidence is rising in women
@oncoalert.bsky.social
acsjournals.onlinelibrary.wiley.com/doi/full/10....
🔺 However, alarming disparities persist
🚺 Cancer incidence is rising in women
@oncoalert.bsky.social
acsjournals.onlinelibrary.wiley.com/doi/full/10....
Reposted by Jasmine Sukumar MD
#SABCS24 #bcsm #OncSky
🧵 COMET study randomized 957 F age 40+ w/ low risk ER+ #DCIS to guideline-concordant care (GCC, immed surgery etc) or active monitoring (AM, serial imaging-> bx/surg etc). At 2y, AM non-inferior to GCC for invasive #breastcancer, BUT important details…
@oncoalert.bsky.social
🧵 COMET study randomized 957 F age 40+ w/ low risk ER+ #DCIS to guideline-concordant care (GCC, immed surgery etc) or active monitoring (AM, serial imaging-> bx/surg etc). At 2y, AM non-inferior to GCC for invasive #breastcancer, BUT important details…
@oncoalert.bsky.social
December 12, 2024 at 11:44 PM
#SABCS24 #bcsm #OncSky
🧵 COMET study randomized 957 F age 40+ w/ low risk ER+ #DCIS to guideline-concordant care (GCC, immed surgery etc) or active monitoring (AM, serial imaging-> bx/surg etc). At 2y, AM non-inferior to GCC for invasive #breastcancer, BUT important details…
@oncoalert.bsky.social
🧵 COMET study randomized 957 F age 40+ w/ low risk ER+ #DCIS to guideline-concordant care (GCC, immed surgery etc) or active monitoring (AM, serial imaging-> bx/surg etc). At 2y, AM non-inferior to GCC for invasive #breastcancer, BUT important details…
@oncoalert.bsky.social
Reposted by Jasmine Sukumar MD
It's a difficult topic to discuss- weight. Hugely personal, not easy to change, but impt.
4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean
2% ⬆️ recurrence in pts with N0 dz
📌Magnitude of effect larger among premeno.
📌ER + AND ER neg
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean
2% ⬆️ recurrence in pts with N0 dz
📌Magnitude of effect larger among premeno.
📌ER + AND ER neg
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
December 12, 2024 at 5:15 PM
It's a difficult topic to discuss- weight. Hugely personal, not easy to change, but impt.
4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean
2% ⬆️ recurrence in pts with N0 dz
📌Magnitude of effect larger among premeno.
📌ER + AND ER neg
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean
2% ⬆️ recurrence in pts with N0 dz
📌Magnitude of effect larger among premeno.
📌ER + AND ER neg
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
Reposted by Jasmine Sukumar MD
#SABCS24 #bcsm #OncSky #MedSky
📣 A germline variant in PCSK9 (V474I) is assoc w/ #breastcancer survival & causally drives mets (targets tumoral LRP1 & induces somatic pro-mets gene expression).
PCSK9 inhibition (used to ⬇️ cholesterol) ⬇️ mets.
@oncoalert.bsky.social
www.cell.com/cell/abstrac...
📣 A germline variant in PCSK9 (V474I) is assoc w/ #breastcancer survival & causally drives mets (targets tumoral LRP1 & induces somatic pro-mets gene expression).
PCSK9 inhibition (used to ⬇️ cholesterol) ⬇️ mets.
@oncoalert.bsky.social
www.cell.com/cell/abstrac...
A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor
Characterization of a common germline variant in PCSK9 unveils a hereditary basis underlying breast cancer metastasis and suggests that PCSK9 inhibition therapy could be a promising strategy for breast cancer metastasis prevention.
www.cell.com
December 13, 2024 at 5:36 PM
#SABCS24 #bcsm #OncSky #MedSky
📣 A germline variant in PCSK9 (V474I) is assoc w/ #breastcancer survival & causally drives mets (targets tumoral LRP1 & induces somatic pro-mets gene expression).
PCSK9 inhibition (used to ⬇️ cholesterol) ⬇️ mets.
@oncoalert.bsky.social
www.cell.com/cell/abstrac...
📣 A germline variant in PCSK9 (V474I) is assoc w/ #breastcancer survival & causally drives mets (targets tumoral LRP1 & induces somatic pro-mets gene expression).
PCSK9 inhibition (used to ⬇️ cholesterol) ⬇️ mets.
@oncoalert.bsky.social
www.cell.com/cell/abstrac...
Reposted by Jasmine Sukumar MD
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
December 13, 2024 at 8:08 PM
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Reposted by Jasmine Sukumar MD
@maryamlustberg.bsky.social presents a summary of survivorship poster presentations #SABCS24 “Health promotion should be done in collaboration with our patients and should not create extra stress for them.” #bcsm
@sabcs.bsky.social @yaleschoolofmed.bsky.social
@sabcs.bsky.social @yaleschoolofmed.bsky.social
December 12, 2024 at 2:32 PM
@maryamlustberg.bsky.social presents a summary of survivorship poster presentations #SABCS24 “Health promotion should be done in collaboration with our patients and should not create extra stress for them.” #bcsm
@sabcs.bsky.social @yaleschoolofmed.bsky.social
@sabcs.bsky.social @yaleschoolofmed.bsky.social